Vaneck Biotech Etf Performance
| BBH Etf | USD 167.03 1.59 0.96% |
The entity has a beta of 0.76, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, VanEck Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding VanEck Biotech is expected to be smaller as well.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days VanEck Biotech ETF has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest inconsistent performance, the Etf's fundamental drivers remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the Etf traders. ...more
1 | Short Interest in VanEck Biotech ETF Expands By 57.1 | 10/28/2024 |
| In Threey Sharp Ratio | -0.39 |
VanEck |
VanEck Biotech Relative Risk vs. Return Landscape
If you would invest 18,113 in VanEck Biotech ETF on August 30, 2024 and sell it today you would lose (1,410) from holding VanEck Biotech ETF or give up 7.78% of portfolio value over 90 days. VanEck Biotech ETF is generating negative expected returns assuming volatility of 1.076% on return distribution over 90 days investment horizon. In other words, 9% of etfs are less volatile than VanEck, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
VanEck Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for VanEck Biotech's investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as VanEck Biotech ETF, and traders can use it to determine the average amount a VanEck Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1141
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BBH |
Estimated Market Risk
| 1.08 actual daily | 9 91% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average VanEck Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VanEck Biotech by adding VanEck Biotech to a well-diversified portfolio.
VanEck Biotech Fundamentals Growth
VanEck Etf prices reflect investors' perceptions of the future prospects and financial health of VanEck Biotech, and VanEck Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VanEck Etf performance.
| Price To Earning | 17.66 X | |||
| Price To Book | 2.74 X | |||
| Price To Sales | 4.72 X | |||
| Total Asset | 478.42 M | |||
About VanEck Biotech Performance
By evaluating VanEck Biotech's fundamental ratios, stakeholders can gain valuable insights into VanEck Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if VanEck Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if VanEck Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
The fund normally invests at least 80 percent of its total assets in securities that comprise the funds benchmark index. Vaneck Biotech is traded on NASDAQ Exchange in the United States.| VanEck Biotech ETF generated a negative expected return over the last 90 days | |
| The fund generated three year return of -5.0% | |
| VanEck Biotech ETF holds 99.96% of its assets under management (AUM) in equities |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in VanEck Biotech ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
The market value of VanEck Biotech ETF is measured differently than its book value, which is the value of VanEck that is recorded on the company's balance sheet. Investors also form their own opinion of VanEck Biotech's value that differs from its market value or its book value, called intrinsic value, which is VanEck Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VanEck Biotech's market value can be influenced by many factors that don't directly affect VanEck Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VanEck Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if VanEck Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VanEck Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.